NCT00743405

Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects

Single-blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a First Time in Human Study to assess the safety, tolerability and pharmacokinetics of single doses of GSK1034702 in healthy subjects. It will be a single-blind, randomized, placebo-controlled, single oral dose, dose-rising, cross-over study in healthy male and female (of non-child bearing potential) subjects. Subjects will be randomized into cohorts of 10 subjects and cohorts will be recruited until the pre-defined safety or PK stopping limits are reached. Each subject will receive placebo and up to 4 doses of GSK1034702 in a randomized sequence on 5 separate study occasions.

Conditions

• Cognitive Disorders

Interventions

Type	Name	Description
DRUG	GSK1034702	Oral or liquid
DRUG	Placebo	To match GSK1034702

Timeline

• Start date: 2008-05-02
• Primary completion: 2008-12-15
• Completion: 2008-12-15
• First posted: 2008-08-28
• Last updated: 2017-07-21

Locations

1 site across 1 country: United Kingdom